Covidien attributes growing vascular strength in Q4 to ev3 purchase
This article was originally published in Clinica
Executive Summary
Covidien is reaping early rewards from its purchase of vascular firm ev3, as evidenced by the group's strong medical devices revenue in the fourth quarter last year.